Novel Nargenicin A1 Analog Inhibits Angiogenesis by Downregulating the Endothelial VEGF/VEGFR2 Signaling and Tumoral HIF-1α/VEGF Pathway

Novel Nargenicin A1 Analog Inhibits Angiogenesis by Downregulating the Endothelial VEGF/VEGFR2 Signaling and Tumoral HIF-1α/VEGF Pathway

Targeting angiogenesis is an attractive strategy for the treatment of angiogenesis-related diseases, including cancer. We previously identified 23-demethyl 8,13-deoxynargenicin (compound <b>9</b>) as a novel nargenicin A1 analog with potential anticancer activity. In this study, we inves...

Full description

Bibliographic Details
Main Authors: Jang Mi Han, Ye Seul Choi, Dipesh Dhakal, Jae Kyung Sohng, Hye Jin Jung
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Biomedicines
Subjects:
angiogenesis
nargenicin A1
compound <b>9</b>
VEGF
VEGFR2
HIF-1α
Online Access:https://www.mdpi.com/2227-9059/8/8/252

Similar Items

Similar Items